Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

RADNOR, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...
September 21, 2017 16:01 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

RADNOR, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
September 19, 2017 16:01 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter’s option to purchase additional shares

RADNOR, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) announced the closing of an underwritten public offering of 10,733,334 shares...
September 15, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

RADNOR, Pa., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 9,333,334 shares...
September 14, 2017 16:01 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Public Offering of Common Stock

RADNOR, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock...
September 11, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe, Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. ...
August 01, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results

Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and...
June 29, 2017 14:28 ET | Source: Marinus Pharmaceuticals, Inc.

FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
June 27, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression

Program to Evaluate Intravenous and Oral Ganaxolone in Patients with Severe or Moderate Postpartum Depression RADNOR, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc....
May 01, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results

RADNOR, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...